Ameriprise Financial Inc. Grows Stock Holdings in Annexon, Inc. (NASDAQ:ANNX)

Ameriprise Financial Inc. raised its stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 483.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 926,642 shares of the company's stock after acquiring an additional 767,869 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.87% of Annexon worth $4,754,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company's stock worth $28,456,000 after buying an additional 576,625 shares during the last quarter. Candriam S.C.A. increased its position in Annexon by 15.6% in the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company's stock worth $13,001,000 after buying an additional 341,431 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Annexon by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company's stock worth $11,142,000 after acquiring an additional 27,843 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Annexon by 20.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,360,076 shares of the company's stock worth $6,977,000 after acquiring an additional 231,034 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Annexon by 6.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,104,385 shares of the company's stock worth $5,667,000 after acquiring an additional 69,733 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Needham & Company LLC cut their price target on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright cut their price target on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Annexon Price Performance

Shares of Annexon stock traded up $0.15 during trading hours on Thursday, reaching $2.18. The company had a trading volume of 826,447 shares, compared to its average volume of 1,781,788. Annexon, Inc. has a one year low of $1.29 and a one year high of $7.85. The business has a fifty day simple moving average of $1.82 and a 200 day simple moving average of $3.35. The firm has a market cap of $239.18 million, a PE ratio of -2.08 and a beta of 1.24.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, research analysts forecast that Annexon, Inc. will post -0.96 EPS for the current year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.